Inclusion Criteria:  Histologically or cytologically (Bethesda 5 or 6) confirmed pancreatic ductal adenocarcinoma. Resectable tumor according to Dutch Pancreatic Cancer Group criteria: no arterial contact and venous contact with the superior mesenteric vein or portal vein of 90 degrees or less No evidence for metastatic disease WHO performance status of 0 or 1 Ability to undergo surgery and mFOLFIRINOX chemotherapy Leucocytes (WBC) ≥ 3.0 x 10^9/L Platelets ≥ 100 x 10^9/L Hemoglobin ≥ 6.0 mmol/l Renal function: eGFR ≥ 40 ml/min Age ≥ 18 years Written informed consent  Exclusion Criteria:  Prior radiotherapy, chemotherapy, or surgery for pancreatic cancer. Prior chemotherapy precluding mFOLFIRINOX. Previous malignancy (excluding non-melanoma skin cancer, pancreatic neuroendocrine tumor (pNET) <2cm, and gastrointestinal stromal tumor (GIST) <2cm), unless no evidence of disease and diagnosed more than 3 years before diagnosis of pancreatic cancer, or with a life expectancy of more than 5 years from date of inclusion. Pregnancy or lactation. Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.